

1

2

Radiofrequency Monitoring of Intracranial Hemorrhage in the Neurological Intensive Care Unit: A Pilot Trial of the SENSE Device

3

4
5 Joseph J. Korfhagen¹ PhD, George J. Shaw^{1,2,*} MD, PhD, Matthew L. Flaherty^{1,3} MD
6 Opeolu Adeoye^{1,4} MD, William A. Knight⁴ MD

7

8 ¹SENSE Diagnostics, Inc., Cincinnati, OH

9 ²Department of Biomedical Engineering, University of Cincinnati, Cincinnati, OH

10 ³Department of Neurology, University of Cincinnati, Cincinnati, OH

11 ⁴Department of Emergency Medicine, University of Cincinnati, Cincinnati, OH

12 *Corresponding Author, Email: gshaw@senseneuro.com

13 *Abstract*

14

15 Intracerebral hemorrhage (ICH) is a devastating form of stroke, with substantial mortality
16 and morbidity. Hemorrhage expansion (HE) occurs in ~40% of patients and portends worse
17 neurologic outcome and mortality. Currently, ICH patients are admitted to the intensive care unit
18 (ICU) and monitored for HE with neurologic exam and neuroimaging. By the time a change is
19 detected, it may be too late to mitigate HE. There is a clinical need for a non-invasive bedside
20 monitor of ICH.

21 The SENSE consists of a 9-antenna array mounted around the head with driving
22 electronics. A 913 MHz signal is transmitted by a given antenna, crosses the intracranial region,
23 and received by the remaining 8 antennae. A complete measurement consists of one cycle with
24 each antenna serving as the transmitting antenna. It was hypothesized that HE of ≥ 3 ml would
25 be detected by the device.

26 Ten ICH subjects admitted within 24 hours of stroke onset were enrolled. All patients
27 received a diagnostic head CT (baseline), and a repeat head CT at 12 (+/- 6) hours. ICH volumes
28 were determined by blinded neuroradiologist reading, and a significant HE from baseline was
29 considered ≥ 3 ml. Subjects were scanned with the device every 10 minutes for up to 72 hours.

30 Data from one subject was lost from operator error. Among the remaining nine, two
31 experienced HE of ≥ 3 ml (3 and 8.2 ml respectively). SENSE device readings were 100%
32 concordant with the CT scan results.

33

34 *Introduction*

35

36 Intracerebral hemorrhage (ICH) is a devastating form of stroke with mortality of 35 to
37 52%. Only 20% of survivors experience full recovery by 6 months (1), and ICH prevalence is
38 expected to rise with the aging population. Current therapy is predominantly supportive (2),
39 although there have been encouraging early results from neuro-interventional trials (3, 4) of
40 stereotactic thrombolysis and acute blood pressure control (Shi 2017). Other approaches include
41 hemostatic agents and coagulation factors with mixed results to date (5).

42 Hemorrhage expansion (HE) in ICH is associated with worse neurologic outcome and increased
43 mortality (6). Davis et al found that for every 1 ml increase in ICH volume, patients were 7%
44 more likely to worsen from independence towards requiring assistance, and from assistance to
45 poor outcome. HE is not uncommon, occurring in about 38% of ICH patients within 20 hours
46 (7).

47 Currently, HE is detected by repeat neuroimaging with CT or MRI, and can lead to
48 significant changes in patient management such as surgical intervention (8).
49 Monitoring for HE after ICH is currently performed by clinical neurological exam and periodic
50 neuroimaging. Clinical exam can be problematic in patients that are sedated and/or intubated.
51 The exam can also lag serious intracranial events. In addition, at most institutions, the patient
52 must be transported to radiology for the imaging which can take substantial time and risk.
53 Finally, none of these techniques can be considered a continuous monitor of the brain and the
54 hemorrhage. There are no current techniques or devices to provide continuous, non-invasive,
55 bedside ICH monitoring in clinical practice.

56 The SENSE (Sensor Evaluation of Neurological Status in Emergencies) device was
57 developed to address this clinical need. SENSE is a radiofrequency (RF) based technique
58 utilizing the differential scattering and absorption of radio waves from intracranial tissues of

59 varying dielectric constant ϵ and conductivity σ (9). Specifically, blood differs substantially in its
60 electrical properties as compared with the grey and white matter of the brain (10). An RF signal
61 incident on a blood collection of differing ϵ and σ from the surrounding tissue induces a time
62 oscillating electric dipole moment in the blood collection (11). This results in a signal generated
63 by the blood collection at the same frequency f of the incident signal, but differing in phase and
64 amplitude, depending on the differing electrical characteristics, location of the blood, and its
65 volume. These combined signals can be measured, and used to determine the presence or
66 absence of significant changes in blood volume over time.

67 The use of microwaves as a potential medical imaging modality has been under
68 development for some time (Semenov 2009). In microwave tomography (MT), microwave
69 signals are scattered from biological tissues. The scattered signal amplitudes are used as input
70 data to invert Maxwell's equations, and obtain ϵ as a function of position within the tissue.
71 Limitations include low dielectric contrast between some soft tissues, and mathematical
72 complexity in solving these equations to obtain ϵ . Other approaches such as AI based analysis
73 have been used in interpreting the scattered signals (Persson 2014) in more focused applications,
74 such as the detection of acute stroke. Overall, these techniques have been focused on imaging or
75 acute diagnosis of general brain pathology, and not as a monitor of changes in such pathology.

76 Korfhagen et al (Korfhagen 2013) demonstrated that a 400 MHz RF signal could detect
77 as little as 1 ml of blood in a validated *in-vitro* brain gel model. They also found that the RF
78 signal scattering was dependent on the geometry of the experimental blood collection. Kandadai
79 et al (Kandadai 2014) demonstrated RF detection of 3 ml of blood in a porcine ICH preparation
80 over a frequency range of 0.4-1 GHz. In addition, they found that the optimal RF frequency for
81 intracranial blood detection was within 0.75 – 1 GHz range.

82 The overall goal of this study was to determine if SENSE could be used safely to monitor
83 and detect ICH expansion in the Neurocritical Care unit. The secondary objective was to
84 determine if SENSE could detect hemorrhage expansion of 3 ml or greater in these patients.

85

86 *Materials and Methods*

87

88 **Study Objectives**

89

90 The overall objective of this prospective, observational, single site, first-in-human pilot
91 study of the SENSE device was to determine if SENSE could safely monitor ICH in the clinical
92 environment. Up to 10 patients could be enrolled. Secondary objectives included human factors
93 information to optimize the design, and operator challenges in the clinical environment. The
94 results of the study were intended to guide further design changes for a planned pivotal clinical
95 trial of the device.

96 The primary endpoint for this early feasibility study was the correlation of SENSE with
97 CT changes over time. An expansion of 3 ml or more in a given ICH was considered significant.

98

99 **Study Population**

100

101 The study population was patients presenting with a diagnosis of spontaneous ICH to a
102 single urban comprehensive stroke center (CSC). Emergency Department based Clinical
103 Research Coordinators (CRC) screened for ICH patients at the study site. Patients were enrolled
104 within 24 hours of symptom onset.

105 In order to be a candidate for the study, ICH patients were 22 years of age or older, with a
106 diagnostic head CT performed within 24 hours of symptom onset, an ICH volume greater than or
107 equal to 1 and less than 90 ml, and able to participate in study procedures. Potential subjects
108 were excluded if pregnant or lactating, had a history of seizure disorder or were on medications
109 that lowered the seizure threshold, had an intraventricular hemorrhage (IVH), subdural
110 hemorrhage (SDH), epidural hemorrhage (EDH), or secondary cause of the ICH, if surgical ICH
111 evacuation or continuous EEG monitoring was planned within 24 hours, or if taking medications
112 that increased hemorrhage risk.

113 Patients were approached by CRCs after the screening process, and enrolled after
114 appropriate written informed consent was obtained from the patient, or approved legal surrogate.
115 Following subject enrollment, the SENSE device was placed on the patient for up to 72 hours.
116 The device performed a scan every 10 minutes, and an individual scan took about 40 seconds.
117 The SENSE data was recorded internally in the device, and later downloaded by study personnel
118 after the monitoring period was complete for a given subject. The treating clinicians were
119 blinded to the SENSE data.

120 For each subject, data recorded included basic subject demographic data, past medical
121 history, and radiologist's interpretation of the neuroimaging studies. Adverse events (AE) and
122 serious adverse events (SAEs) were noted and recorded.

123 The study protocol was approved by the FDA under and IDE and by the local IRB.

124

125 **Imaging Protocol**

126

127 The following CT imaging protocol was followed for each subject:

- 128 • Diagnosis: CT Scan 1 – standard of care; diagnostic head CT scan within 24 hours of
129 symptom onset.
- 130 • First Study CT: CT Scan 2 – study CT; first study CT scan as soon as practicable after
131 informed consent, followed by SENSE monitoring within 15 minutes of completion of
132 the first CT scan.
- 133 • 12 Hours: CT Scan 3 – standard of care; CT scan 12 (± 6) hours after first study CT scan.
- 134 • 72 Hours: CT Scan 4 – study CT; end of study CT scan 72 (± 12) hours after first study
135 CT scan.

136 Study eligibility ICH volumes were calculated from the diagnostic CT by clinical and/or research
137 staff using the ABC method (12). Subsequently, ICH and edema volumes were determined by a
138 neuroradiologist blinded to the clinical and SENSE device data. Quantification of volumes were
139 performed using computer-assisted methods. The blinded evaluator was required to place seed-
140 points within the volume of interest and adjust lower and upper intensity Hounsfield unit (HU)
141 thresholds until the entire volume was correctly selected.

142

143 **SENSE Device**

144

145 The SENSE device was comprised of two segments; a headset worn by the patient
146 (Figure 1), and the controlling electronics (not shown). These two items were connected by a
147 semi-rigid cable. The headpiece contained 9 circular microwave patch antennae with an
148 operating frequency of 913 MHz. The total power radiated for a given antenna when active was
149 1 mW.

150 The antenna array was configured as 3 sagittal arrays of 3 antenna each; one in the
151 midline of the patient's head, and the remaining on the left and right sides respectively. The
152 antennae were offset from direct contact with a given subject's head by a foam insulating pad.
153 All antennae were approximately oriented radially towards the center of the intracranial region.
154 All patient-contacting materials and electronics underwent and passed approved biological and
155 electronic safety testing prior to use.

156 For a given measurement, one antenna would transmit the incident signal, and the
157 remaining 8 received the altered signal as modified by absorption and scattering from
158 intracranial tissues. In a single measurement, all 9-antenna served as the transmitting antenna,
159 thus yielding 72 total measurements. For a cycle, the measurement would be repeated for 10
160 iterations. A single cycle took about 40 seconds. The data were stored on a secured internal hard
161 drive of the driving electronics, and were downloaded by study personnel once data acquisition
162 for the given patient was completed. Patients were scanned every 10 minutes during the study
163 period.

164 **SENSE Data**

165
166 Methods used in the SENSE algorithm were developed from in vitro and in vivo porcine
167 experiments (9, 13). First, for each pair of antennae, the raw voltage data was compared to the
168 first, or baseline, measurement. This value was denoted Δ_{TR} , where T is the transmitting antenna
169 and R is the receiving antenna. Then, for this time point, delta values for all pairs were
170 compared. By comparing the delta values to a set of threshold values, the change was determined
171 to be due to a change in the ICH volume, edema development, movement, or system drift. While
172 the SENSE device can detect changes due to both increases and decreases (due to clot retraction)
173 in hemorrhage size, only increases in hemorrhage volume greater than 3 mL were considered
174 significant and were denoted as active bleeding.

175 *Results*

176 **Subjects**

177
178 A total of 10 patients were enrolled from May through October 2017, and 9 completed
179 the protocol. The average age was 57 years (range: 43-70), and there were 5 female subjects.
180 Details of the ICH locations and volumes are shown in Table 1. Patients were monitored with
181 SENSE for an average of 60 (range: 23-72) hours. There were no Serious Adverse Events.
182 Adverse events were predominantly minor skin and nose irritation from the nosepiece of the
183 headset.

184 **CTs**

185
186 The initial head CT for these patients showed an average ICH volume of 24.5 (SD 19.7)
187 ml. Of the 10 patients, 9 completed the protocol. The SENSE data for one patient was lost due to
188 operator error of the device. Of the remaining 9 patients, 2 had a significant expansion of 3.0 and
189 8.2 ml, respectively. The expansion for both patients occurred within 12 hours of onset, and was
190 demonstrated on the 12-hour study CT.

191
192
193
194
195

196 **SENSE**

197

198 As shown in Table 1, the SENSE data was 100% concordant with the CT results. The
199 SENSE signals showed significant changes in time for the two expansions, and did not show any
200 such changes for the 7 patients who did not experience a hemorrhage expansion.

201

202 *Discussion*

203

204 In summary, the SENSE device was used to safely monitor ICH patients in a clinical
205 environment. In addition, it was able to detect HE of ≥ 3 ml in this prospective, single-site pilot
206 trial. Significant limitations include the small sample size n of 10 patients, and the single-site
207 limits the generalizability of our results. However, these results are promising, and certainly
208 warrant further study.

209 Currently, ICH patients are monitored by serial neurologic exam, and neuroimaging. In
210 addition, intracranial pressure monitoring (ICP) is sometimes utilized in a subset of patients
211 (Tuan 2013). However to the authors' knowledge, there are no non-invasive monitors of ICH in
212 current clinical use. In addition, the clinical exam may be difficult in a sedated and/or paralyzed
213 and intubated patient such that a neurological exam is not possible. Also HE can occur in such
214 patients, and may not be detected for hours, depending on the schedule of neuroimaging. There is
215 clearly a clinical need for such a monitor, and the results presented here suggest that RF
216 monitoring may be a useful approach.

217

218 *Author Contributions Statement*

219

220 All authors planned and designed the study. JJ wrote the grant, obtained the data, and performed
221 the data analysis. GJ performed data analysis and drafted the manuscript. OA and ML assisted in
222 grant preparation, and reviewed the manuscript. WK assisted in study design, served as site PI,
223 and reviewed the manuscript.

224

225 *Funding*

226

227 This work was funded by the National Science Foundation under grant SBIR Phase II 1632270.

228

229 *Conflicts*

230

231 JK is an employee of and owns shares of SENS Diagnostics, Inc.

232 GJ, OA and ML are co-inventors of a patent underlying the SENSE device, and owns shares in
233 SENSE Diagnostics, Inc,

234 WK has no conflicts

235

236

237

238

239

240

241

242
243
244
245
246
247
248
249
250
251
252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286 **Table 1: ICH Characteristics**

ICH Location	Initial V (ml)	V (12 h)	V (72 h)	12 h ICH Expansion
R BG,Thalamus	1	1		
L BG, Thalamus, IC	3.8	3.8	3.2	
L Lobar	20.2	20.6	18	
BG	22	25	20	Y
R Lobar	35.1	33.4	30.4	
L BG, thalamus, IC	24.8	23.5	18.3	
R BS, Cerebellar	12.7	20.9		Y
L BG	12.3	11.3	11.2	
L Lobar	61.4	59.5	51.7	
L BG, Thalamus, IC, Caudate Nucleus	51.5	50.4	48.9	

287

288

289

290 **Figure 1:** SENSE headset piece (controlling electronics not shown). The antenna array (9 total)
291 is contained within the headpiece, along with appropriate wiring. The antenna signals are input
292 and output via a cable (not shown) that communicates with the control box.

293



294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309 **References**

310 1. Caceres JA, Goldstein JN. Intracranial hemorrhage. *Emerg Med Clin North Am.* 2012;30(3):771-
311 94.

312 2. Dastur CK, Yu W. Current management of spontaneous intracerebral haemorrhage. *Stroke and*
313 *Vascular Neurology.* 2017;2(1):21.

314 3. Hersh EH, Gologorsky Y, Chartrain AG, Mocco J, Kellner CP. Minimally Invasive Surgery for
315 Intracerebral Hemorrhage. *Current Neurology and Neuroscience Reports*
316 2018;18 (6)(34).

317 4. Awad IA, Polster SP, Carrion-Penagos J, Thompson RE, Cao Y, Stadnik A, et al. Surgical
318 Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus
319 Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE)
320 Procedure. *Neurosurgery.* 2019;84(6):1157-68.

321 5. Al-Shahi Salman R, Law ZK, Bath PM, Steiner T, Sprigg N. Haemostatic therapies for acute
322 spontaneous intracerebral haemorrhage. *The Cochrane database of systematic reviews.*
323 2018;4:Cd005951.

324 6. Davis SM, Broderick J, Hennerici M, Brun NC, Dinger MN, Mayer SA, et al. Hematoma growth is
325 a determinant of mortality and poor outcome after intracerebral hemorrhage. *Neurology.*
326 2006;66(8):1175-81.

327 7. de Oliveira Manoel AL, Goffi A, Zampieri FG, Turkel-Parrella D, Duggal A, Marotta TR, et al. The
328 critical care management of spontaneous intracranial hemorrhage: a contemporary review. *Critical care*
329 *(London, England).* 2016;20:272-.

330 8. Maas MB, Rosenberg NF, Kosteva AR, Bauer RM, Guth JC, Liotta EM, et al. Surveillance
331 neuroimaging and neurologic examinations affect care for intracerebral hemorrhage. *Neurology.*
332 2013;81(2):107-12.

333 9. Korfhagen JJ, Kandadai MA, Clark JF, Adeoye O, Shaw GJ. A prototype device for non-invasive
334 continuous monitoring of intracerebral hemorrhage. *J Neurosci Methods.* 2013;213(1):132-7.

335 10. Gabriel S, Lau RW, Gabriel C. The dielectric properties of biological tissues: II. Measurements in
336 the frequency range 10 Hz to 20 GHz. *Phys Med Biol.* 1996;41(11):2251-69.

337 11. Griffiths DJ. *Introduction to Electrodynamics.* 4 ed. Cambridge: Cambridge University Press;
338 2017.

339 12. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, et al. The ABCs of
340 measuring intracerebral hemorrhage volumes. *Stroke.* 1996;27(8):1304-5.

341 13. Kandadai MA, Korfhagen JJ, Beiler S, Beiler C, Wagner K, Adeoye OM, et al. In vivo testing of a
342 non-invasive prototype device for the continuous monitoring of intracerebral hemorrhage. *J Neurosci*
343 *Methods.* 2014;235:117-22.

344 14. Klahr AC, Kate M, Kosior J, Buck B, Shuaib A, Emery D, et al. Early hematoma retraction in
345 intracerebral hemorrhage is uncommon and does not predict outcome. *PLoS one.*
346 2018;13(10):e0205436-e.

347

348

349

350

351

352

353

354